amifostine anhydrous has been researched along with Ewing Sarcoma in 4 studies
Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Topotecan had limited activity in patients with Ewing sarcoma or PNET metastatic at diagnosis." | 5.12 | Intensive therapy with growth factor support for patients with Ewing tumor metastatic at diagnosis: Pediatric Oncology Group/Children's Cancer Group Phase II Study 9457--a report from the Children's Oncology Group. ( Bernstein, ML; Devidas, M; Dickman, PS; Dubowy, R; Gebhardt, M; Goorin, A; Grier, HE; Lafreniere, D; Link, MP; Meyers, PA; Nicholas, R; Perlman, EJ; Souid, AK; Stine, K; Wainer, IW, 2006) |
| " Adequate dosing of either drug is necessary for protecting the cells from toxic effects of alkylating agents." | 1.31 | Blood thiols following amifostine and mesna infusions, a pediatric oncology group study. ( Aktas, MK; Bernstein, ML; Dubowy, RL; Fahey, RC; Karjoo, S; Newton, GL; Sadowitz, PD; Sayin, OA; Souid, AK, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bernstein, ML | 3 |
| Devidas, M | 1 |
| Lafreniere, D | 1 |
| Souid, AK | 3 |
| Meyers, PA | 1 |
| Gebhardt, M | 1 |
| Stine, K | 1 |
| Nicholas, R | 1 |
| Perlman, EJ | 1 |
| Dubowy, R | 1 |
| Wainer, IW | 1 |
| Dickman, PS | 1 |
| Link, MP | 1 |
| Goorin, A | 1 |
| Grier, HE | 1 |
| Margulies, BS | 1 |
| Damron, TA | 1 |
| Allen, MJ | 1 |
| Fahey, RC | 2 |
| Dubowy, RL | 2 |
| Newton, GL | 2 |
| Aktas, MK | 1 |
| Sayin, OA | 1 |
| Karjoo, S | 1 |
| Sadowitz, PD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| INTENSIVE THERAPY WITH GROWTH FACTOR SUPPORT FOR PATIENTS WITH EWING'S TUMOR METASTATIC AT DIAGNOSIS: A PEDIATRIC ONCOLOGY GROUP PHASE II STUDY[NCT00002643] | Phase 2 | 130 participants (Actual) | Interventional | 1995-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for amifostine anhydrous and Ewing Sarcoma
| Article | Year |
|---|---|
Intensive therapy with growth factor support for patients with Ewing tumor metastatic at diagnosis: Pediatric Oncology Group/Children's Cancer Group Phase II Study 9457--a report from the Children's Oncology Group.
Topics: Adolescent; Adult; Amifostine; Bone Neoplasms; Child; Child, Preschool; Cyclophosphamide; Female; Hu | 2006 |
WR-2721 (amifostine) infusion in patients with Ewing's sarcoma receiving ifosfamide and cyclophosphamide with mesna: drug and thiol levels in plasma and blood cells, a Pediatric Oncology Group study.
Topics: Adolescent; Adult; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Blood Cells; Bone Neo | 1999 |
2 other studies available for amifostine anhydrous and Ewing Sarcoma
| Article | Year |
|---|---|
The differential effects of the radioprotectant drugs amifostine and sodium selenite treatment in combination with radiation therapy on constituent bone cells, Ewing's sarcoma of bone tumor cells, and rhabdomyosarcoma tumor cells in vitro.
Topics: Amifostine; Animals; Bone Neoplasms; Cell Line, Tumor; Cell Survival; Drug Screening Assays, Antitum | 2008 |
Blood thiols following amifostine and mesna infusions, a pediatric oncology group study.
Topics: Adolescent; Adult; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Child; Chromatography | 2001 |